Hester Biosciences (HESTERBIO) Fundamentals 2026 — P/E 36.3x, Revenue Analysis | SniperIQ
Hester Biosciences (HESTERBIO) is a India-listed Healthcare company in Drug Manufacturers - Specialty & Generic with a market capitalization of ₹2,068 Crore, trading at ₹2431.00 on the NSE. This SniperIQ fundamentals page covers Hester Biosciences's valuation (P/E 36.3x, P/B 5.5x), profitability (net margin 16.7%), revenue (₹333 Crore in FY2026), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Hester Biosciences's market cap?
Hester Biosciences (HESTERBIO) has a market capitalization of approximately ₹2,068 Crore, trading at ₹2431.00 on the NSE. Market cap moves with the live share price.
What is Hester Biosciences's P/E ratio?
Hester Biosciences's trailing twelve-month P/E ratio is 36.3x, with a price-to-book (P/B) of 5.5x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Hester Biosciences?
Hester Biosciences runs a net profit margin of 16.7%, a gross margin of 62.7%, and an operating margin of 20.4%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Hester Biosciences generate?
Hester Biosciences reported revenue of ₹333 Crore for fiscal year 2026, with net income of ₹56 Crore and earnings per share (EPS) of 67.57. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Hester Biosciences pay a dividend?
Hester Biosciences offers a trailing dividend yield of about 0.5%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.
Is Hester Biosciences financially healthy?
Hester Biosciences carries a debt-to-equity ratio of 0.54x and a current ratio of 1.37x, with a market beta of 0.49. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Hester Biosciences a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Hester Biosciences (HESTERBIO) the key facts are: market cap ₹2,068 Crore, P/E 36.3x, revenue ₹333 Crore, 52-week range 1239.3-2660. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track Hester Biosciences's full fundamentals live
Get Hester Biosciences's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.